In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of UroGen Pharma Ltd (NASDAQ: URGN) closed at $15.27 in the last session, down -0.91% from day before closing price of $15.41. In other words, the price has decreased by -$0.91 from its previous closing price. On the day, 1.2 million shares were traded. URGN stock price reached its highest trading level at $15.8 during the session, while it also had its lowest trading level at $14.89.
Ratios:
We take a closer look at URGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.47 and its Current Ratio is at 5.65.
On April 16, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $23.Scotiabank initiated its Sector Outperform rating on April 16, 2025, with a $23 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 09 ’25 when Schoenberg Mark sold 5,162 shares for $7.37 per share. The transaction valued at 38,044 led to the insider holds 153,378 shares of the business.
Schoenberg Mark bought 5,162 shares of URGN for $38,044 on Jun 09 ’25. On Jan 31 ’25, another insider, Schoenberg Mark, who serves as the Chief Medical Officer of the company, sold 4,551 shares for $11.14 each. As a result, the insider received 50,698 and left with 145,666 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 704061568 and an Enterprise Value of 562145088. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.68. Its current Enterprise Value per Revenue stands at 6.119 whereas that against EBITDA is -5.274.
Stock Price History:
The Beta on a monthly basis for URGN is 1.11, which has changed by -0.05740738 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $17.00, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is 47.51%, while the 200-Day Moving Average is calculated to be 39.03%.
Shares Statistics:
According to the various share statistics, URGN traded on average about 3.05M shares per day over the past 3-months and 1110450 shares per day over the past 10 days. A total of 46.10M shares are outstanding, with a floating share count of 39.70M. Insiders hold about 14.08% of the company’s shares, while institutions hold 96.63% stake in the company. Shares short for URGN as of 1749772800 were 6125129 with a Short Ratio of 1.79, compared to 1747267200 on 5586633. Therefore, it implies a Short% of Shares Outstanding of 6125129 and a Short% of Float of 13.56.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of UroGen Pharma Ltd (URGN) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.5 and low estimates of -$0.74.
Analysts are recommending an EPS of between -$2.24 and -$3.47 for the fiscal current year, implying an average EPS of -$2.88. EPS for the following year is -$1.03, with 7.0 analysts recommending between $2.04 and -$3.09.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $23.13M. It ranges from a high estimate of $25.9M to a low estimate of $21M. As of the current estimate, UroGen Pharma Ltd’s year-ago sales were $21.85MFor the next quarter, 8 analysts are estimating revenue of $33.69M. There is a high estimate of $40.6M for the next quarter, whereas the lowest estimate is $28.2M.
A total of 8 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $136.5M, while the lowest revenue estimate was $112.13M, resulting in an average revenue estimate of $123.91M. In the same quarter a year ago, actual revenue was $90.4MBased on 8 analysts’ estimates, the company’s revenue will be $258.88M in the next fiscal year. The high estimate is $391.48M and the low estimate is $224.3M.
